From biochemical markers to molecular endotypes of osteoarthritis : a review on validated biomarkers
(2024) In Expert Review of Molecular Diagnostics 24(1-2). p.23-38- Abstract
Introduction: Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated with chronic use. No disease-modifying therapies have been approved to date leaving surgical joint replacement as a last resort. To enable effective patient care and successful drug development there is an urgent need to uncover the pathobiological drivers of OA and how these translate into disease endotypes. Endotypes provide a more precise and mechanistic definition of disease subgroups than observable phenotypes, and a panel of tissue- and pathology-specific biochemical markers may uncover treatable endotypes of OA. Areas... (More)
Introduction: Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated with chronic use. No disease-modifying therapies have been approved to date leaving surgical joint replacement as a last resort. To enable effective patient care and successful drug development there is an urgent need to uncover the pathobiological drivers of OA and how these translate into disease endotypes. Endotypes provide a more precise and mechanistic definition of disease subgroups than observable phenotypes, and a panel of tissue- and pathology-specific biochemical markers may uncover treatable endotypes of OA. Areas covered: We have searched PubMed for full-text articles written in English to provide an in-depth narrative review of a panel of validated biochemical markers utilized for endotyping of OA and their association to key OA pathologies. Expert opinion: As utilized in IMI-APPROACH and validated in OAI-FNIH, a panel of biochemical markers may uncover disease subgroups and facilitate the enrichment of treatable molecular endotypes for recruitment in therapeutic clinical trials. Understanding the link between biochemical markers and patient-reported outcomes and treatable endotypes that may respond to given therapies will pave the way for new drug development in OA.
(Less)
- author
- Hannani, Monica T. ; Thudium, Christian S. ; Karsdal, Morten A. ; Ladel, Christoph ; Mobasheri, Ali ; Uebelhoer, Melanie ; Larkin, Jonathan ; Bacardit, Jaume ; Struglics, André LU and Bay-Jensen, Anne Christine
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biochemical marker, biomarker, bone remodeling, cartilage, endotype, endotyping, osteoarthritis, patient stratification
- in
- Expert Review of Molecular Diagnostics
- volume
- 24
- issue
- 1-2
- pages
- 16 pages
- publisher
- Future Drugs Ltd
- external identifiers
-
- scopus:85185527916
- pmid:38353446
- ISSN
- 1473-7159
- DOI
- 10.1080/14737159.2024.2315282
- language
- English
- LU publication?
- yes
- id
- 37da0583-1ee4-4ced-b239-5f0cd6cb5af6
- date added to LUP
- 2024-03-19 15:55:08
- date last changed
- 2025-02-07 00:58:40
@article{37da0583-1ee4-4ced-b239-5f0cd6cb5af6,
abstract = {{<p>Introduction: Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated with chronic use. No disease-modifying therapies have been approved to date leaving surgical joint replacement as a last resort. To enable effective patient care and successful drug development there is an urgent need to uncover the pathobiological drivers of OA and how these translate into disease endotypes. Endotypes provide a more precise and mechanistic definition of disease subgroups than observable phenotypes, and a panel of tissue- and pathology-specific biochemical markers may uncover treatable endotypes of OA. Areas covered: We have searched PubMed for full-text articles written in English to provide an in-depth narrative review of a panel of validated biochemical markers utilized for endotyping of OA and their association to key OA pathologies. Expert opinion: As utilized in IMI-APPROACH and validated in OAI-FNIH, a panel of biochemical markers may uncover disease subgroups and facilitate the enrichment of treatable molecular endotypes for recruitment in therapeutic clinical trials. Understanding the link between biochemical markers and patient-reported outcomes and treatable endotypes that may respond to given therapies will pave the way for new drug development in OA.</p>}},
author = {{Hannani, Monica T. and Thudium, Christian S. and Karsdal, Morten A. and Ladel, Christoph and Mobasheri, Ali and Uebelhoer, Melanie and Larkin, Jonathan and Bacardit, Jaume and Struglics, André and Bay-Jensen, Anne Christine}},
issn = {{1473-7159}},
keywords = {{Biochemical marker; biomarker; bone remodeling; cartilage; endotype; endotyping; osteoarthritis; patient stratification}},
language = {{eng}},
number = {{1-2}},
pages = {{23--38}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Molecular Diagnostics}},
title = {{From biochemical markers to molecular endotypes of osteoarthritis : a review on validated biomarkers}},
url = {{http://dx.doi.org/10.1080/14737159.2024.2315282}},
doi = {{10.1080/14737159.2024.2315282}},
volume = {{24}},
year = {{2024}},
}